Mary X. D. O’Riordan is an American molecular biologist who is the Frederick C. Neidhardt Collegiate Professor of Microbiology and Immunology at the University of Michigan. She also serves as Dean for Graduate and Postdoctoral Studies at Michigan Medicine.
Mary X. D. O’Riordan | |
|---|---|
 O'Riordan in 2015 | |
| Alma mater | University of California, San Francisco Princeton University University of Washington |
| Scientific career | |
| Institutions | University of California, Berkeley University of Michigan |
| Thesis | Transcriptional control of early B cell differentiation (1999) |
Early life and education
editO'Riordan earned an undergraduate degree in biology from the University of Washington and an M.A. in molecular biology from Princeton University,[1] then joined the University of California, San Francisco as a doctoral researcher. Her research considered early B cell differentiation.[2] After earning her doctorate, O'Riordan moved to the University of California, Berkeley as a postdoctoral fellow.[1]
Research and career
editIn 2003, O'Riordan joined the faculty at the University of Michigan. O'Riordan studies the interactions of bacterial pathogens with their hosts, and innate immune responses to bacterial infection.[3][4] She is particularly interested in the mechanisms that underpin how the Gram-positive bacterium Listeria monocytogenes interacts with the cellular environment. She is also interested in how the pathogens regulate infection.
O'Riordan discovered the endoplasmic reticulum becomes stressed during lupus, which activates ERN1.[5] ERN1 released neutrophil extracellular traps from lupus neutrophils, which trigger autoantibody formation and contribute to blood vessel clotting.[5]
Academic service
editO'Riordan was inducted into the University of Michigan Medical School League of Educational Excellence in 2013.[6] In 2014, O'Riordan was named a Kavli Foundation fellow.[7][8] In June 2015, O'Riordan was appointed Dean of Graduate & Postdoctoral Studies at the University of Michigan Medical School.[9] She was named the Frederick C. Neidhardt Collegiate Professor in 2018.[10]
Selected publications
edit- T. Reya; M. O'Riordan; R. Okamura; E. Devaney; K. Willert; R. Nusse; R. Grosschedl (1 July 2000). "Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism". Immunity. 13 (1): 15–24. doi:10.1016/S1074-7613(00)00004-2. ISSN 1074-7613. PMID 10933391. Wikidata Q28585177.
- Victoria Auerbuch; Dirk G Brockstedt; Nicole Meyer-Morse; Mary O'Riordan; Daniel A Portnoy (9 August 2004). "Mice lacking the type I interferon receptor are resistant to Listeria monocytogenes". Journal of Experimental Medicine. 200 (4): 527–533. doi:10.1084/JEM.20040976. ISSN 0022-1007. PMC 2211930. PMID 15302899. Wikidata Q36399578.
- M O'Riordan; R Grosschedl (1 July 1999). "Coordinate regulation of B cell differentiation by the transcription factors EBF and E2A". Immunity. 11 (1): 21–31. doi:10.1016/S1074-7613(00)80078-3. ISSN 1074-7613. PMID 10435576. Wikidata Q40937465.
References
edit- ^ a b "Mary O'Riordan, Ph.D. | Immunology | Michigan Medicine". University of Michigan Faculty. 2019-09-19. Retrieved 2022-05-04.
- ^ O'Riordan, Mary X. D (1999). Transcriptional control of early B cell differentiation (Thesis). OCLC 50305033.
- ^ "2014 Kavli Fellows - News Release". www.nasonline.org. Retrieved 2022-05-04.
- ^ "How Mitochondria Deploy a Powerful Punch Against Life-Threatening Bacteria". University of Michigan. Retrieved 2022-05-04.
- ^ a b "Research group identifies potential therapeutic target for lupus". EurekAlert!. Retrieved 2022-05-04.
- ^ "League of Educational Excellence". University of Michigan Medical School. 2017-01-10. Retrieved 2022-05-04.
- ^ "2014 Kavli Fellows - News Release". www.nasonline.org. Retrieved 2022-05-04.
- ^ Science, Kavli Frontiers of (2014-04-17), Cell-Cell Communication and Signaling - Mary, O'Riordan, University of Michigan, retrieved 2022-05-04
- ^ "Mary O'Riordan". ASM.org. Retrieved 2022-05-04.
- ^ "Professorships | Medicine at Michigan". www.medicineatmichigan.org. Retrieved 2022-05-04.